文献速递甲状腺疾病

靶向治疗用于未分化甲状腺癌治疗的真实世界经验

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2017-12-21

单中心回顾性研究纳入16例临床试验外接受靶向治疗的未分化甲状腺癌患者,10例(8例BRAF野生型、2例BRAFV600E突变)接受仑伐替尼,6例BRAFV600E突变者接受达拉非尼联合曲美替尼;全队列部分缓解6/16(38%),中位无进展生存期3.7个月,中位总生存期6.3个月,不良事件可管理。

要点

  • 全队列6/16(38%)部分缓解,6/16(38%)疾病稳定,2/16(12%)疾病进展。
  • 中位无进展生存期全队列3.7个月,仑伐替尼2.7个月,达拉非尼联合曲美替尼5.2个月。
  • 中位总生存期全队列6.3个月,仑伐替尼3.9个月,达拉非尼联合曲美替尼9.3个月。

核心结论

  • 靶向治疗仑伐替尼及达拉非尼联合曲美替尼(用于BRAFV600E突变者)可能为无法参加临床试验的未分化甲状腺癌患者提供临床获益,且毒性可管理。

研究设计与样本

  • 2015年4月至2016年5月单中心学术机构的回顾性综述,研究16例在临床试验外接受靶向治疗的未分化甲状腺癌患者;10例(8例BRAF野生型、2例BRAFV600E突变)接受仑伐替尼,6例BRAFV600E突变者接受达拉非尼联合曲美替尼。

主要发现

  • 多数患者(63%)为男性,治疗时所有患者均有远处转移或放疗抵抗的原发疾病。
  • 全队列中6/16(38%)达部分缓解,6/16(38%)疾病稳定,2/16(12%)疾病进展,2例(12%)在重新分期前死亡。
  • 中位随访时间11.8个月;中位无进展生存期全队列3.7个月[置信区间1.8-7.6],仑伐替尼2.7个月,达拉非尼联合曲美替尼5.2个月。
  • 中位总生存期全队列6.3个月[置信区间1.8-7.6],仑伐替尼3.9个月,达拉非尼联合曲美替尼9.3个月。
  • 不良事件与预期一致且可管理。

关键数值与推荐

  • 最佳疗效采用RECIST v1.1评估,并测定无进展生存期和总生存期,不良事件用于安全性评价。

临床怎么用

  • 作者认为,对于无法参加临床试验的未分化甲状腺癌患者,仑伐替尼及达拉非尼联合曲美替尼(用于BRAFV600E突变者)可能提供临床获益,且毒性可管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial. METHODS: This is a retrospective review from April 2015 to May 2016 at a single academic institution where 16 ATC patients receiving targeted therapy outside of a clinical trial were studied. Ten patients (eight BRAF wild type and two BRAFV600E mutant tumors) were started on lenvatinib, and six with BRAFV600E-mutated tumors received a combination of dabrafenib plus trametinib. Best response evaluated by RECIST v1.1, progression-free survival, and overall survival were determined. Adverse events were evaluated for safety. RESULTS: The majority of patients (63%) were men, and all had distant metastases or radiation-resistant primary disease at the time of treatment. In the entire cohort, 6/16 (38%) had a partial response, 6/16 (38%) had stable disease, and 2/16 (12%) had progressive disease. Two (12%) patients died before restaging. Median follow-up time was 11.8 months. Median progression-free survival was 3.7 months [confidence interval 1.8-7.6] in the entire cohort, 2.7 months for lenvatinib, and 5.2 months for dabrafenib plus trametinib. Median OS was 6.3 months [confidence interval 1.8-7.6] for the entire cohort, 3.9 months for lenvatinib, and 9.3 months for dabrafenib plus trametinib. Adverse events were as expected and manageable. CONCLUSIONS: Targeted therapies, lenvatinib, and dabrafenib plus trametinib (for BRAFV600E mutants) may provide clinical benefit in ATC patients who are unable to participate in clinical trials, and toxicities are manageable.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Iyer PC, Dadu R, Ferrarotto R, et al. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2017. PMID: 29161986. doi:10.1089/thy.2017.0285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。